Get to know our clinical trials
Ensayo con enmascaramiento doble tras tratamiento quirúrgico y radioterapia en pacientes con carcinoma epidermoide cutáneo de alto riesgo.
THE MAIN OBJECTIVE OF THIS STUDY IS TO DETERMINE WHETHER CEMIPLIMAB CAN PREVENT THE RECURRENCE OF CUTANEOUS SQUAMOUS CELL CARCINOMA AFTER SURGICAL TREATMENT AND RADIOTHERAPY.
Technical Summary
- RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY OF ADJUVANT CEMIPLIMAB COMPARED WITH PLACEBO AFTER SURGICAL TREATMENT AND RADIOTHERAPY IN PATIENTS WITH HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA.
- Code EudraCT: 2019-000566-38
- Protocol number: R2810-ONC-1788
- Promoter: Regeneron Pharmaceuticals, Inc.
- Molecule/Drug: cemiplimab
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Who can participate?
Trial with double masking after surgical treatment and radiotherapy in patients with high-risk cutaneous squamous cell carcinoma.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.